Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 10/10

vs
industry
vs
history
Cash-to-Debt No Debt
NYSE:GMED's Cash-to-Debt is ranked higher than
86% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. NYSE:GMED: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
NYSE:GMED' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Equity-to-Asset 0.90
NYSE:GMED's Equity-to-Asset is ranked higher than
94% of the 294 Companies
in the Global Medical Devices industry.

( Industry Median: 0.63 vs. NYSE:GMED: 0.90 )
Ranked among companies with meaningful Equity-to-Asset only.
NYSE:GMED' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.83  Med: 0.86 Max: 0.9
Current: 0.9
0.83
0.9
Interest Coverage No Debt
NYSE:GMED's Interest Coverage is ranked higher than
89% of the 221 Companies
in the Global Medical Devices industry.

( Industry Median: 97.42 vs. NYSE:GMED: No Debt )
Ranked among companies with meaningful Interest Coverage only.
NYSE:GMED' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 20.76
Beneish M-Score: -2.34
WACC vs ROIC
7.86%
25.11%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 31.43
NYSE:GMED's Operating Margin % is ranked higher than
97% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 2.42 vs. NYSE:GMED: 31.43 )
Ranked among companies with meaningful Operating Margin % only.
NYSE:GMED' s Operating Margin % Range Over the Past 10 Years
Min: 23.4  Med: 29.56 Max: 31.61
Current: 31.43
23.4
31.61
Net Margin % 21.20
NYSE:GMED's Net Margin % is ranked higher than
93% of the 299 Companies
in the Global Medical Devices industry.

( Industry Median: 1.92 vs. NYSE:GMED: 21.20 )
Ranked among companies with meaningful Net Margin % only.
NYSE:GMED' s Net Margin % Range Over the Past 10 Years
Min: 15.79  Med: 19.02 Max: 20.7
Current: 21.2
15.79
20.7
ROE % 15.78
NYSE:GMED's ROE % is ranked higher than
82% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 1.20 vs. NYSE:GMED: 15.78 )
Ranked among companies with meaningful ROE % only.
NYSE:GMED' s ROE % Range Over the Past 10 Years
Min: 15.98  Med: 17.49 Max: 43.04
Current: 15.78
15.98
43.04
ROA % 13.85
NYSE:GMED's ROA % is ranked higher than
92% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 0.07 vs. NYSE:GMED: 13.85 )
Ranked among companies with meaningful ROA % only.
NYSE:GMED' s ROA % Range Over the Past 10 Years
Min: 13.54  Med: 14.67 Max: 36.91
Current: 13.85
13.54
36.91
ROC (Joel Greenblatt) % 64.28
NYSE:GMED's ROC (Joel Greenblatt) % is ranked higher than
90% of the 316 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. NYSE:GMED: 64.28 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NYSE:GMED' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 59.22  Med: 69.97 Max: 139.86
Current: 64.28
59.22
139.86
3-Year Revenue Growth Rate 10.60
NYSE:GMED's 3-Year Revenue Growth Rate is ranked higher than
73% of the 224 Companies
in the Global Medical Devices industry.

( Industry Median: 3.80 vs. NYSE:GMED: 10.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NYSE:GMED' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 10.6  Med: 10.7 Max: 13.5
Current: 10.6
10.6
13.5
3-Year EBITDA Growth Rate 12.30
NYSE:GMED's 3-Year EBITDA Growth Rate is ranked higher than
60% of the 193 Companies
in the Global Medical Devices industry.

( Industry Median: 4.10 vs. NYSE:GMED: 12.30 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NYSE:GMED' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 4.5  Med: 9.9 Max: 12.3
Current: 12.3
4.5
12.3
3-Year EPS without NRI Growth Rate 13.50
NYSE:GMED's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 190 Companies
in the Global Medical Devices industry.

( Industry Median: 2.40 vs. NYSE:GMED: 13.50 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NYSE:GMED' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 6.8  Med: 13.1 Max: 13.5
Current: 13.5
6.8
13.5
GuruFocus has detected 3 Warning Signs with Globus Medical Inc $NYSE:GMED.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NYSE:GMED's 10-Y Financials

Financials (Next Earnings Date: 2017-02-27)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

GMED Guru Trades in Q1 2016

John Hussman 200,000 sh (New)
Jim Simons 346,700 sh (New)
Joel Greenblatt 218,985 sh (New)
Paul Tudor Jones 100,283 sh (+236.88%)
John Paulson Sold Out
» More
Q2 2016

GMED Guru Trades in Q2 2016

Joel Greenblatt 621,101 sh (+183.63%)
Paul Tudor Jones 117,497 sh (+17.17%)
Steven Cohen 200,000 sh (unchged)
John Hussman Sold Out
Jim Simons 104,700 sh (-69.80%)
» More
Q3 2016

GMED Guru Trades in Q3 2016

Joel Greenblatt 732,178 sh (+17.88%)
Steven Cohen 300,000 sh (unchged)
Jim Simons Sold Out
Paul Tudor Jones 84,093 sh (-28.43%)
» More
Q4 2016

GMED Guru Trades in Q4 2016

Steven Cohen 414,380 sh (New)
Mario Gabelli 19,900 sh (New)
Joel Greenblatt 157,283 sh (-78.52%)
Paul Tudor Jones 11,200 sh (-86.68%)
» More
» Details

Insider Trades

Latest Guru Trades with GMED

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Devices » Medical Devices    NAICS: 339112    SIC: 3841
Compare:NYSE:NVRO, NAS:WMGI, NAS:LIVN, OTCPK:GGNDF, NAS:IART, OTCPK:EKTAF, OTCPK:NHNKY, OTCPK:FSPKF, NAS:NUVA, NAS:CYNO, NAS:INGN, OTCPK:IOBCF, NAS:BABY, NAS:SPNC, NAS:CNMD, NYSE:ITGR, NAS:MASI, NAS:CSII, NAS:MDXG, NAS:OFIX » details
Traded in other countries:GM0N.Germany,
Globus Medical Inc is a medical device company focused on developing products that promote healing in patients with musculoskeletal disorders.

Globus Medical Inc was incorporated in Delaware in March 3, 2003. The Company is a medical device company focused exclusively on the design, development and commercialization of musculoskeletal implants. It is currently focused on implants that promote healing in patients with spine disorders. All of its products fall into one of two categories: Innovative Fusion or Disruptive Technologies. The Company's Innovative Fusion products address a spinal fusion surgical procedures. Spinal fusion is a surgical procedure to correct problems with the individual vertebrae, the interlocking bones making up the spine, by preventing movement of the affected bones. It currently offers over 120 products for the treatment of spine disorders. Products in Innovative Fusion includes: CREO, a convenient non-threaded locking cap design that eases building of thoracolumbar fixation constructs to readily adapt to the patient's anatomy and condition, for a range of clinical applications. XPAND, FORTIFY, FORTIFY-I corpectomy devices that incorporate smooth expansion capability, have a range of size options for optimal fit, and are manufactured from titanium or radiolucent polyetheretherketone. COALITION and INDEPENDENCE stand-alone interbody fusion devices, simplify the surgical technique by reducing steps and hardware while providing confident stabilization. Disruptive Technologies represent a shift in the treatment of spine disorders by allowing for novel surgical procedures, improvements to existing surgical procedures, and the treatment of spine disorders by new physician specialties, and surgical intervention earlier in the continuum of care. Products in Disruptive Technologies includes: MIS products which enable a surgeon to perform a procedure less invasively to minimize tissue disruption and maximize native anatomy, for patient recovery and fewer approach-related complications. For example, MARS 3V retractor system facilitates smaller incisions with the use of positionable radiolucent retractor blades to access the surgical site and to allow both direct and radiographic visualization. CALIBER, RISE and recently launched LATIS expandable interbody spacers are designed for reliable, minimally disruptive delivery through small MIS incisions with streamlined implants and instruments. REVOLVE pedicle screw system is designed for MIS screw and rod insertion through small incisions, and utilizes a convenient non-threaded locking cap design. TRANSITION, provide for stabilization that is less rigid than traditional pedicle screw systems for more natural load distribution to help promote fusion while maintaining stability. Other products included are SECURE-C, SECURE-CR, KINEX, MICROFUSE, SHIELD, AFFIRM, among others. Company's competitors include: Medtronic, the DePuy Synthes Companies, Stryker and NuVasive. Alphatec Spine, Orthofix International, Zimmer, LDR, among others. As of December 31, 2013, the Company owned 188 issued U.S. patents and had applicat

Ratios

vs
industry
vs
history
PE Ratio 23.52
GMED's PE Ratio is ranked higher than
58% of the 172 Companies
in the Global Medical Devices industry.

( Industry Median: 25.50 vs. GMED: 23.52 )
Ranked among companies with meaningful PE Ratio only.
GMED' s PE Ratio Range Over the Past 10 Years
Min: 12.96  Med: 22.87 Max: 35.64
Current: 23.52
12.96
35.64
Forward PE Ratio 22.68
GMED's Forward PE Ratio is ranked higher than
57% of the 56 Companies
in the Global Medical Devices industry.

( Industry Median: 23.92 vs. GMED: 22.68 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 23.52
GMED's PE Ratio without NRI is ranked higher than
58% of the 168 Companies
in the Global Medical Devices industry.

( Industry Median: 25.48 vs. GMED: 23.52 )
Ranked among companies with meaningful PE Ratio without NRI only.
GMED' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.96  Med: 22.87 Max: 35.64
Current: 23.52
12.96
35.64
Price-to-Owner-Earnings 25.09
GMED's Price-to-Owner-Earnings is ranked higher than
61% of the 103 Companies
in the Global Medical Devices industry.

( Industry Median: 30.29 vs. GMED: 25.09 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
GMED' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 18.52  Med: 24.47 Max: 74.62
Current: 25.09
18.52
74.62
PB Ratio 3.39
GMED's PB Ratio is ranked lower than
51% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.17 vs. GMED: 3.39 )
Ranked among companies with meaningful PB Ratio only.
GMED' s PB Ratio Range Over the Past 10 Years
Min: 2.45  Med: 3.59 Max: 4.94
Current: 3.39
2.45
4.94
PS Ratio 4.98
GMED's PS Ratio is ranked lower than
68% of the 307 Companies
in the Global Medical Devices industry.

( Industry Median: 3.29 vs. GMED: 4.98 )
Ranked among companies with meaningful PS Ratio only.
GMED' s PS Ratio Range Over the Past 10 Years
Min: 2.47  Med: 4.23 Max: 5.61
Current: 4.98
2.47
5.61
Price-to-Free-Cash-Flow 22.44
GMED's Price-to-Free-Cash-Flow is ranked higher than
60% of the 106 Companies
in the Global Medical Devices industry.

( Industry Median: 27.61 vs. GMED: 22.44 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GMED' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 16.57  Med: 28.46 Max: 75.46
Current: 22.44
16.57
75.46
Price-to-Operating-Cash-Flow 16.83
GMED's Price-to-Operating-Cash-Flow is ranked higher than
60% of the 135 Companies
in the Global Medical Devices industry.

( Industry Median: 18.12 vs. GMED: 16.83 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GMED' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 12.43  Med: 19.94 Max: 32.2
Current: 16.83
12.43
32.2
EV-to-EBIT 14.29
GMED's EV-to-EBIT is ranked higher than
74% of the 169 Companies
in the Global Medical Devices industry.

( Industry Median: 21.48 vs. GMED: 14.29 )
Ranked among companies with meaningful EV-to-EBIT only.
GMED' s EV-to-EBIT Range Over the Past 10 Years
Min: 6.5  Med: 13.3 Max: 21.3
Current: 14.29
6.5
21.3
EV-to-EBITDA 12.32
GMED's EV-to-EBITDA is ranked higher than
65% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 15.79 vs. GMED: 12.32 )
Ranked among companies with meaningful EV-to-EBITDA only.
GMED' s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.6  Med: 11.45 Max: 17.9
Current: 12.32
5.6
17.9
PEG Ratio 2.10
GMED's PEG Ratio is ranked higher than
59% of the 76 Companies
in the Global Medical Devices industry.

( Industry Median: 2.33 vs. GMED: 2.10 )
Ranked among companies with meaningful PEG Ratio only.
GMED' s PEG Ratio Range Over the Past 10 Years
Min: 1.39  Med: 1.55 Max: 1.88
Current: 2.1
1.39
1.88
Current Ratio 7.27
GMED's Current Ratio is ranked higher than
89% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 2.45 vs. GMED: 7.27 )
Ranked among companies with meaningful Current Ratio only.
GMED' s Current Ratio Range Over the Past 10 Years
Min: 4.88  Med: 6.87 Max: 10.12
Current: 7.27
4.88
10.12
Quick Ratio 5.51
GMED's Quick Ratio is ranked higher than
86% of the 313 Companies
in the Global Medical Devices industry.

( Industry Median: 1.79 vs. GMED: 5.51 )
Ranked among companies with meaningful Quick Ratio only.
GMED' s Quick Ratio Range Over the Past 10 Years
Min: 3.82  Med: 5.56 Max: 8.29
Current: 5.51
3.82
8.29
Days Inventory 297.94
GMED's Days Inventory is ranked lower than
83% of the 281 Companies
in the Global Medical Devices industry.

( Industry Median: 130.88 vs. GMED: 297.94 )
Ranked among companies with meaningful Days Inventory only.
GMED' s Days Inventory Range Over the Past 10 Years
Min: 125.66  Med: 265.53 Max: 269.63
Current: 297.94
125.66
269.63
Days Sales Outstanding 57.03
GMED's Days Sales Outstanding is ranked higher than
65% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 66.78 vs. GMED: 57.03 )
Ranked among companies with meaningful Days Sales Outstanding only.
GMED' s Days Sales Outstanding Range Over the Past 10 Years
Min: 50.59  Med: 52.05 Max: 58.04
Current: 57.03
50.59
58.04
Days Payable 38.72
GMED's Days Payable is ranked lower than
69% of the 254 Companies
in the Global Medical Devices industry.

( Industry Median: 58.05 vs. GMED: 38.72 )
Ranked among companies with meaningful Days Payable only.
GMED' s Days Payable Range Over the Past 10 Years
Min: 28.24  Med: 43.9 Max: 52.36
Current: 38.72
28.24
52.36

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -1.50
GMED's 3-Year Average Share Buyback Ratio is ranked higher than
61% of the 199 Companies
in the Global Medical Devices industry.

( Industry Median: -3.90 vs. GMED: -1.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
GMED' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -1.6  Med: -1.5 Max: -0.8
Current: -1.5
-1.6
-0.8

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 16.49
GMED's Price-to-Net-Cash is ranked higher than
52% of the 114 Companies
in the Global Medical Devices industry.

( Industry Median: 17.13 vs. GMED: 16.49 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GMED' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 6.32  Med: 13.02 Max: 31.3
Current: 16.49
6.32
31.3
Price-to-Net-Current-Asset-Value 7.12
GMED's Price-to-Net-Current-Asset-Value is ranked lower than
51% of the 234 Companies
in the Global Medical Devices industry.

( Industry Median: 6.59 vs. GMED: 7.12 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GMED' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 3.2  Med: 5.83 Max: 7.36
Current: 7.12
3.2
7.36
Price-to-Tangible-Book 4.35
GMED's Price-to-Tangible-Book is ranked higher than
51% of the 283 Companies
in the Global Medical Devices industry.

( Industry Median: 4.24 vs. GMED: 4.35 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GMED' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.65  Med: 3.94 Max: 5.51
Current: 4.35
2.65
5.51
Price-to-Median-PS-Value 1.18
GMED's Price-to-Median-PS-Value is ranked lower than
64% of the 262 Companies
in the Global Medical Devices industry.

( Industry Median: 0.99 vs. GMED: 1.18 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GMED' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.59  Med: 0.98 Max: 1.34
Current: 1.18
0.59
1.34
Price-to-Peter-Lynch-Fair-Value 1.88
GMED's Price-to-Peter-Lynch-Fair-Value is ranked lower than
58% of the 53 Companies
in the Global Medical Devices industry.

( Industry Median: 1.74 vs. GMED: 1.88 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
GMED' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 1.48  Med: 1.48 Max: 1.48
Current: 1.88
Price-to-Graham-Number 2.14
GMED's Price-to-Graham-Number is ranked higher than
50% of the 139 Companies
in the Global Medical Devices industry.

( Industry Median: 2.06 vs. GMED: 2.14 )
Ranked among companies with meaningful Price-to-Graham-Number only.
GMED' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.24  Med: 2.07 Max: 2.96
Current: 2.14
1.24
2.96
Earnings Yield (Greenblatt) % 7.00
GMED's Earnings Yield (Greenblatt) % is ranked higher than
87% of the 337 Companies
in the Global Medical Devices industry.

( Industry Median: -0.30 vs. GMED: 7.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GMED' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 4.7  Med: 7.5 Max: 15.4
Current: 7
4.7
15.4
Forward Rate of Return (Yacktman) % 15.12
GMED's Forward Rate of Return (Yacktman) % is ranked higher than
67% of the 123 Companies
in the Global Medical Devices industry.

( Industry Median: 8.88 vs. GMED: 15.12 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
GMED' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: 15.1  Med: 15.7 Max: 16.1
Current: 15.12
15.1
16.1

More Statistics

Revenue (TTM) (Mil) $555.0
EPS (TTM) $ 1.22
Beta0.73
Short Percentage of Float11.99%
52-Week Range $19.25 - 28.70
Shares Outstanding (Mil)95.83

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 561 625 684 716
EPS ($) 1.19 1.27 1.44 1.55
EPS without NRI ($) 1.19 1.27 1.44 1.55
EPS Growth Rate
(Future 3Y To 5Y Estimate)
10.05%
Dividends per Share ($)
» More Articles for NYSE:GMED

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Globus Medical Inc, Diplomat Pharmacy Inc, Zendesk Inc, and Amicus Thera Mar 28 2015 

More From Other Websites
Globus Medical to Present at Leerink Partners 6th Annual Global Healthcare Conference 2017 Feb 09 2017
Globus Medical Schedules Fourth Quarter and Full Year 2016 Earnings Release and Conference Call Feb 07 2017
GLOBUS MEDICAL INC Files SEC form 8-K, Results of Operations and Financial Condition Jan 10 2017
Globus Medical Reports Preliminary Fourth Quarter and Full Year Sales Results Jan 10 2017
Globus Medical Announces CE Mark for Excelsius GPS™ Jan 05 2017
Globus Medical Announces CE Mark for Excelsius GPS™ Jan 05 2017
ETFs with exposure to Globus Medical, Inc. : January 3, 2017 Jan 03 2017
ETFs with exposure to Globus Medical, Inc. : December 19, 2016 Dec 19 2016
ETFs with exposure to Globus Medical, Inc. : December 6, 2016 Dec 06 2016
Globus Medical, Inc. breached its 50 day moving average in a Bullish Manner : GMED-US : December 6,... Dec 06 2016
Hedge Funds Are Ditching Globus Medical Inc (GMED): Have They Uncovered Something You Haven’t? Dec 04 2016
Globus Medical and UMB Financial Set to Join S&P MidCap 400; HomeStreet to Join S&P SmallCap 600 Dec 02 2016
Coverage initiated on Globus Medical by Aegis Capital Nov 30 2016
ETFs with exposure to Globus Medical, Inc. : November 18, 2016 Nov 18 2016
GLOBUS MEDICAL INC Financials Nov 17 2016
Globus Medical, Inc. :GMED-US: Earnings Analysis: Q3, 2016 By the Numbers : November 16, 2016 Nov 16 2016
GLOBUS MEDICAL INC Files SEC form 10-Q, Quarterly Report Nov 09 2016
Analysts' Actions -- F5 Networks, GoPro, Lockheed Martin, U.S. Steel and More Nov 09 2016
Edited Transcript of GMED earnings conference call or presentation 8-Nov-16 10:30pm GMT Nov 09 2016
Globus Medical Reports Third Quarter 2016 Results Nov 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)